Intellia Therapeutics (NASDAQ: NTLA)
Intellia Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intellia Therapeutics Company Info
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
News & Analysis
2 Stocks Down 30% to Buy Right Now
These stocks have plenty of catalysts ahead.
Is Intellia Therapeutics Stock a Buy Now?
The company's future will depend on its innovative qualities.
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular money manager added to these three existing positions on Monday following disappointing financial updates earlier this month.
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Good news may be on the way, but it will be a while before it arrives.
Is It Too Late to Buy Intellia Therapeutics Stock?
2024 could be an important year for the biotech.
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024.
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.
Valuation
Earnings Transcripts
Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript
NTLA earnings call for the period ending October 3, 2021.
Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript
NTLA earnings call for the period ending June 30, 2021.
Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript
NTLA earnings call for the period ending March 31, 2021.
Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript
NTLA earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.